Alan Tan, MD, discusses upcoming trials that could change the landscape of frontline and adjuvant renal cell carcinoma ...

Opens in a new tab or window Share on Bluesky ... et al "Emerging novel functional imaging and immunotherapy in renal cell carcinoma and current treatment sequencing strategies after immunotherapy ...

Researchers report that all nine patients in a clinical trial being treated for stage III or IV clear cell renal cell carcinoma (a form of kidney cancer), generated a successful anti-cancer immune ...

Patients with advanced kidney cancer who received an experimental vaccine after their tumors were removed were still ...

Thomas Hutson, DO, PharmD, discusses key takeaways from the phase 3 CLEAR trial evaluating lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma.

In a small clinical trial of nine patients with stage III and IV kidney cancer, a personalized anti-tumor vaccine generated ...

Researchers evaluated a neoantigen-targeting personalized cancer vaccine in patients with high-risk, fully resected clear ...

A personalized neoantigen cancer vaccine generated strong immune responses in renal cell carcinoma patients, leading to ...

Cancer researchers are one step closer to developing an effective vaccine to treat people with clear cell renal cell ...

Dana-Farber Cancer Institute researchers will present important research studies during the 2025 ASCO Genitourinary (GU) ...

Personalized vaccine targets key driver mutations and induces antitumor immunity in fully resected high-risk clear cell renal cell carcinoma.

Two new measures tied to outcomes drawn from data in the CLEAR phase 3 trial will be presented during the ASCO Genitourinary ...